Amgen Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AMGN Nasdaq 2830 www.amgen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amgen Inc.

Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Mar 14th, 2025 4:15 pm
Amgen’s gMG therapy cuts disease symptoms at one-year mark - Mar 13th, 2025 5:31 pm
Amgen (NasdaqGS:AMGN) Announces Promising MINT Trial Data For UPLIZNA In Generalized Myasthenia Gravis - Mar 13th, 2025 5:21 pm
Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds? - Mar 13th, 2025 4:09 pm
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year - Mar 13th, 2025 3:36 pm
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue? - Mar 13th, 2025 3:30 pm
Amgen Says Phase 3 Data Support Uplizna's Efficacy in Generalized Myasthenia Gravis - Mar 13th, 2025 1:58 pm
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Mar 13th, 2025 1:50 pm
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS - Mar 13th, 2025 1:00 pm
Amgen Inc. (AMGN): Among Dobermans of the Dow to Buy - Mar 12th, 2025 2:04 pm
HALO vs. AMGN: Which Stock Is the Better Value Option? - Mar 11th, 2025 3:40 pm
Stock market sell-off: Why these stocks are in the green amid the pain - Mar 10th, 2025 6:17 pm
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies - Mar 10th, 2025 1:27 pm
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints - Mar 10th, 2025 11:30 am
Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus - Mar 10th, 2025 10:35 am
3 Magnificent Growth Stocks to Buy in March - Mar 8th, 2025 3:41 pm
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS - Mar 8th, 2025 11:00 am
Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound? - Mar 7th, 2025 4:31 pm
2 Dividend Stocks to Buy for a Lifetime of Passive Income - Mar 7th, 2025 10:03 am
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup - Mar 7th, 2025 10:00 am